AU2015328273B2 - Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof - Google Patents

Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof Download PDF

Info

Publication number
AU2015328273B2
AU2015328273B2 AU2015328273A AU2015328273A AU2015328273B2 AU 2015328273 B2 AU2015328273 B2 AU 2015328273B2 AU 2015328273 A AU2015328273 A AU 2015328273A AU 2015328273 A AU2015328273 A AU 2015328273A AU 2015328273 B2 AU2015328273 B2 AU 2015328273B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015328273A
Other languages
English (en)
Other versions
AU2015328273A1 (en
Inventor
De-Kuan Chang
Wayne A. Marasco
Quan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2015328273A1 publication Critical patent/AU2015328273A1/en
Application granted granted Critical
Publication of AU2015328273B2 publication Critical patent/AU2015328273B2/en
Priority to AU2020286302A priority Critical patent/AU2020286302B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015328273A 2014-10-06 2015-10-06 Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof Active AU2015328273B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020286302A AU2020286302B2 (en) 2014-10-06 2020-12-10 Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060381P 2014-10-06 2014-10-06
US62/060,381 2014-10-06
PCT/US2015/054202 WO2016057488A1 (en) 2014-10-06 2015-10-06 Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020286302A Division AU2020286302B2 (en) 2014-10-06 2020-12-10 Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2015328273A1 AU2015328273A1 (en) 2017-04-20
AU2015328273B2 true AU2015328273B2 (en) 2020-09-17

Family

ID=54337425

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015328273A Active AU2015328273B2 (en) 2014-10-06 2015-10-06 Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
AU2020286302A Active AU2020286302B2 (en) 2014-10-06 2020-12-10 Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020286302A Active AU2020286302B2 (en) 2014-10-06 2020-12-10 Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof

Country Status (7)

Country Link
US (4) US10675349B2 (https=)
EP (2) EP3204418B1 (https=)
JP (3) JP6795505B2 (https=)
CN (2) CN107250160B (https=)
AU (2) AU2015328273B2 (https=)
CA (1) CA2962949C (https=)
WO (1) WO2016057488A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6795505B2 (ja) * 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3508206A4 (en) * 2016-09-01 2020-04-29 Bebeachibuli, Romeo Food factor-based formulation, products produced using said formulation and methods for producing same
JP7269167B2 (ja) 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same
JP7277255B2 (ja) * 2018-05-31 2023-05-18 佳寛 大矢 インビトロでの制御性ｔ細胞の特異性評価方法
WO2020113224A2 (en) 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
EP3927731A4 (en) * 2019-02-19 2022-12-28 The Regents of the University of Colorado, a body corporate BISPECIFIC IMMUNOTOXINS FOR TARGETING HUMAN CD25S-CCR4+ TUMORS AND REGULATORY T-CELLS
AU2020253060B2 (en) * 2019-03-29 2025-09-25 Universität Zürich Fc-modified biologicals for local delivery to compartments, in particular to the CNS
CN114051532A (zh) * 2019-05-24 2022-02-15 希望之城公司 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞
AU2020290579B2 (en) 2019-06-14 2026-02-12 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1 and methods of use thereof
CN111704668B (zh) * 2020-06-27 2021-03-30 天津金域医学检验实验室有限公司 抗ccr4抗体及其在治疗癌症中的应用
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166500A1 (en) * 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
GB8426467D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993004701A1 (en) 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CN100455599C (zh) * 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
JP2003208610A (ja) 2002-01-16 2003-07-25 Noritsu Koki Co Ltd 画像処理装置、画像処理方法、画像処理プログラム、および画像処理プログラムを記録した記録媒体
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
GB201020738D0 (en) * 2010-12-07 2011-01-19 Affitech Res As Antibodies
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
JP6795505B2 (ja) * 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166500A1 (en) * 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
JP2020193210A (ja) 2020-12-03
AU2020286302A1 (en) 2021-01-21
JP7589204B2 (ja) 2024-11-25
AU2015328273A1 (en) 2017-04-20
US20250339521A1 (en) 2025-11-06
US11723973B2 (en) 2023-08-15
CA2962949A1 (en) 2016-04-14
US20170290911A1 (en) 2017-10-12
EP3204418B1 (en) 2020-03-25
US20240115697A1 (en) 2024-04-11
CN114634571A (zh) 2022-06-17
CA2962949C (en) 2024-03-05
WO2016057488A1 (en) 2016-04-14
JP7129449B2 (ja) 2022-09-01
EP3699196A1 (en) 2020-08-26
JP2017537972A (ja) 2017-12-21
EP3204418A1 (en) 2017-08-16
US12337034B2 (en) 2025-06-24
AU2020286302B2 (en) 2024-03-21
CN107250160B (zh) 2022-01-11
US20210000950A1 (en) 2021-01-07
US10675349B2 (en) 2020-06-09
JP6795505B2 (ja) 2020-12-02
JP2022159548A (ja) 2022-10-17
CN107250160A (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
AU2020286302B2 (en) Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
US9587028B2 (en) Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
AU2015327781A1 (en) Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
HK40076088A (en) Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)